
Opinion|Videos|January 10, 2025
Assessing New Therapies for Retinal Diseases
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- New Therapies:
- Aflibercept 8 mg
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: The case for earlier surgical intervention in diabetic macular edema
2
Retina World Congress 2026: Uveitis risk rises as immune checkpoint inhibitor use expands
3
The Retina TL;DR with Dr. Weng: Navigating the ocular risks of facial fillers with Jennifer Murdock, MD
4
Retina World Congress 2026: Sunir J. Garg, MD, FACS, on preventing occupational injury in retina practice
5























